Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.6753
-0.0042 (-0.62%)
At close: Jun 27, 2025, 4:00 PM
0.6870
+0.0117 (1.73%)
After-hours: Jun 27, 2025, 7:42 PM EDT

Xilio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
9.276.34----
Upgrade
Gross Profit
9.276.34----
Upgrade
Selling, General & Admin
27.1524.782729.9523.8610.65
Upgrade
Research & Development
39.0841.2152.1459.251.1943.91
Upgrade
Operating Expenses
66.2365.9979.1389.1575.0454.56
Upgrade
Operating Income
-56.96-59.65-79.13-89.15-75.04-54.56
Upgrade
Interest Expense
-0.1-0.1-0.7-0.8-0.6-0.6
Upgrade
Other Non Operating Income (Expenses)
2.742.443.431.73-0.16-0.06
Upgrade
EBT Excluding Unusual Items
-54.31-57.3-76.4-88.22-75.8-55.22
Upgrade
Merger & Restructuring Charges
0.01-0.94----
Upgrade
Pretax Income
-54.3-58.24-76.4-88.22-75.8-55.22
Upgrade
Net Income
-54.3-58.24-76.4-88.22-75.8-55.22
Upgrade
Net Income to Common
-54.3-58.24-76.4-88.22-75.8-55.22
Upgrade
Shares Outstanding (Basic)
6554272761
Upgrade
Shares Outstanding (Diluted)
6554272761
Upgrade
Shares Change (YoY)
136.13%94.62%0.38%388.59%970.34%27.97%
Upgrade
EPS (Basic)
-0.83-1.09-2.78-3.22-13.52-105.42
Upgrade
EPS (Diluted)
-0.83-1.09-2.78-3.22-13.52-105.42
Upgrade
Free Cash Flow
21.04-18.41-69.11-77.59-81.85-38.28
Upgrade
Free Cash Flow Per Share
0.32-0.34-2.51-2.83-14.60-73.08
Upgrade
Gross Margin
100.00%100.00%----
Upgrade
Operating Margin
-614.16%-940.18%----
Upgrade
Profit Margin
-585.54%-918.05%----
Upgrade
Free Cash Flow Margin
226.91%-290.26%----
Upgrade
EBITDA
-55.26-58-77.23-87.3-73.55-53.5
Upgrade
D&A For EBITDA
1.71.641.91.851.51.07
Upgrade
EBIT
-56.96-59.65-79.13-89.15-75.04-54.56
Upgrade
Revenue as Reported
9.276.34----
Upgrade
Updated May 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q